Cargando…
Dupilumab-Associated Sezary Syndrome
Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13), approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD). While recent reports have described cases of new-onset mycosis fungoides (MF) following treatment with dupilumab for...
Autores principales: | Hamp, Austin, Hanson, Jamie, Alhatem, Albert, Schwartz, Robert A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564184/ https://www.ncbi.nlm.nih.gov/pubmed/37822402 http://dx.doi.org/10.4103/ijd.ijd_580_22 |
Ejemplares similares
-
Alemtuzumab in refractory Sézary syndrome
por: Reifs, Carmen María Alcántara, et al.
Publicado: (2016) -
Pembrolizumab-associated tumor development in a patient with Sézary syndrome
por: Malachowski, Stephen J., et al.
Publicado: (2019) -
A rare association of bullous pemphigoid with mycosis fungoides and Sézary syndrome
por: Egger, Andjela, et al.
Publicado: (2020) -
Sezary syndrome, thyroid carcinoma, and renal carcinoma in a patient with Poland syndrome
por: Kuzyk, Alexandra, et al.
Publicado: (2021) -
Successful treatment of Sezary syndrome with extracorporeal photopheresis – The first attempt in India
por: Tiwari, Aseem K., et al.
Publicado: (2019)